Drug intelligence / Profile preview

Gd-DO3A

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules
Administration: Intratumoral

Overview

Gd-DO3A is a gadolinium(III)-based magnetic resonance imaging (MRI) contrast agent. It functions by enhancing the signal in MR images, primarily by shortening the T1 relaxation time of water protons in tissues. In the provided context, it was used as a control agent in a study involving B16 melanoma tumor xenografts, where its washout kinetics were compared to a thiol-reactive derivative, Gd-DO3A-PDP. Unlike Gd-DO3A-PDP, Gd-DO3A itself does not possess specific targeting capabilities for exofacial protein thiols (EPTs) and acts as a more general extracellular contrast agent.

Beyond the preview

Go deeper on Gd-DO3A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gd-DO3A.

Explore the full profile